Roche's Genentech Announces Late-Breaking Data From The Phase III OCARINA II Study
Portfolio Pulse from Benzinga Newsdesk
Roche's Genentech announced late-breaking Phase III results showing that subcutaneous injection of Ocrevus was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks. The safety profile of Ocrevus subcutaneous injection was consistent with the well-established safety profile of Ocrevus IV infusion. The 10-minute subcutaneous injection has potential to improve the treatment experience and expand usage for people with multiple sclerosis (MS) in centers with IV capacity limitations.
October 11, 2023 | 7:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive Phase III results for Roche's Ocrevus subcutaneous injection could potentially boost the company's market share in the MS treatment market.
The positive results from the Phase III study of Ocrevus subcutaneous injection indicate that the drug is effective and safe. This could lead to increased usage, especially in centers with IV capacity limitations, potentially boosting Roche's market share in the MS treatment market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
The positive Phase III results for Roche's Ocrevus subcutaneous injection could potentially boost the company's market share in the MS treatment market.
The positive results from the Phase III study of Ocrevus subcutaneous injection indicate that the drug is effective and safe. This could lead to increased usage, especially in centers with IV capacity limitations, potentially boosting Roche's market share in the MS treatment market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
The positive Phase III results for Roche's Ocrevus subcutaneous injection could potentially boost the company's market share in the MS treatment market.
The positive results from the Phase III study of Ocrevus subcutaneous injection indicate that the drug is effective and safe. This could lead to increased usage, especially in centers with IV capacity limitations, potentially boosting Roche's market share in the MS treatment market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100